This Stock Soared 9,800% in 2025. Here's 1 Key Reason Why Investors Are Piling In (Spoiler: It's Regencell Bioscience Holdings (RGC) Stock)
Key Points
Regencell Bioscience looks like a risky bet.
It's generated zero revenue for several years in a row.
Also, its valuation seems way out of line.
- 10 stocks we like better than Regencell Bioscience ›
Shares of Regencell Bioscience Holdings (NASDAQ: RGC) have been on quite a ride since their 2021 initial public offering (IPO), surging 9,800% year to date (as of Nov. 19). That's enough to drive many investors to buy.
Why are they buying this growth stock? Some are simply hoping the shares will keep surging. (That's not a great reason, though.) Others are excited by the company's focus: "We are an early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder."
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
An exciting mission is great, but you should demand more of any stock you invest in. In Regencell's case, a glance at its financials shows that it has posted $0 in revenue for 2021, 2022, 2023, 2024, and 2025. And with zero on its top line, it's not surprising that its bottom line has been in the red for each of those years.
Image source: Getty Images.
Interestingly, the company executed a 38-for-1 stock split in June, after the share price ran up some 60,000%. (Stock splits are more typically 2-for-1 or 3-for-1.) Stock splits tend to get some investors overly excited at the prospect of owning many more shares, but they don't really do much. If you owned 100 shares at $50 apiece for a total value of $5,000 before a 38-for-1 split, you'd own 3,800 shares worth around $1.32 each post-split...for a total value around $5,000. (Stock prices get adjusted proportionately downward in a split.)
As my colleague Sean Williams has pointed out, Regencell doesn't even seem to be close to having any kind of commercial winner. That's fine for an early-stage biotech company, but concerning when we're discussing a company like Regencell, with a recent market cap topping $6 billion.
Fortunately, you don't have to be one of those investors piling in. You can focus on one of many terrific growth stocks with actual products and growth, or on one or more fast-growing exchange-traded funds (ETFs).
Should you invest $1,000 in Regencell Bioscience right now?
Before you buy stock in Regencell Bioscience, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Regencell Bioscience wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $562,536!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,096,510!*
Now, it’s worth noting Stock Advisor’s total average return is 981% — a market-crushing outperformance compared to 187% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of November 17, 2025
Selena Maranjian has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
